CME/CE

Faculty: Roger A. Goldberg, MD, MBA Faculty: Christina Y. Weng, MD, MBA, FASRS This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The s...

Faculty: Katherine E. Talcott, MD Faculty: Roger A. Goldberg, MD, MBA This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series fur...

Faculty: Christina Y. Weng, MD, MBA, FASRS Faculty: Katherine E. Talcott, MD This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The ser...

Faculty: Katherine E. Talcott, MD Faculty: Roger A. Goldberg, MD, MBA This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series fur...

Faculty: Christina Y. Weng, MD, MBA, FASRS Faculty: Katherine E. Talcott, MD This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The ser...

Faculty: Roger A. Goldberg, MD, MBA Faculty: Christina Y. Weng, MD, MBA, FASRS This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The s...

Faculty: Katherine E. Talcott, MD Faculty: Roger A. Goldberg, MD, MBA This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series fur...

Faculty: Christina Y. Weng, MD, MBA, FASRS Faculty: Katherine E. Talcott, MD This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The ser...

Faculty: Katherine E. Talcott, MD Faculty: Roger A. Goldberg, MD, MBA This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series fur...

Faculty: Jonathan Barratt, MD, PhD Professor Jonathan Barratt illustrates the integration of shared decision-making in the management of IgA nephropathy while interacting with a real patient with IgAN, highlighting how patient-centered conversations about proteinuria, GFR, and blood pressure can guide individualized treatment strategies. Emphasis is placed on explaining diagnostic findings such as...

Faculty: Jonathan Barratt, MD, PhD Professor Jonathan Barratt illustrates the integration of shared decision-making in the management of IgA nephropathy while interacting with a real patient with IgAN, highlighting how patient-centered conversations about proteinuria, GFR, and blood pressure can guide individualized treatment strategies. Emphasis is placed on explaining diagnostic findings such as...

Faculty: Ellie Kelepouris, MD, FACP, FAHA Faculty: Nihar Desai, MD Using a real-world patient case, Drs. Ellie Kelepouris and Nihar Desai examine clinical challenges in managing hyperkalemia among patients with chronic kidney disease (CKD) and heart failure (HF). They explore the use of modern potassium binders to sustain guideline-directed medical therapy (GDMT) with renin–angiotensin–aldosterone...

Faculty: Steven Fishbane, MD Faculty: Maurizio Gallieni, MD Drs. Steven Fishbane and Maurizio Gallieni discuss chronic kidney disease-associated pruritus (CKD-aP), a prevalent and under-recognized complication of CKD. They review the epidemiology, pathophysiology, and treatment strategies supported by pivotal phase 3 trials and new European S2k guidelines, including the use of difelikefalin, a kap...

Faculty: Ellie Kelepouris, MD, FACP, FAHA Faculty: Nihar Desai, MD Using a real-world patient case, Drs. Ellie Kelepouris and Nihar Desai examine clinical challenges in managing hyperkalemia among patients with chronic kidney disease (CKD) and heart failure (HF). They explore the use of modern potassium binders to sustain guideline-directed medical therapy (GDMT) with renin–angiotensin–aldosterone...

Faculty: Steven Fishbane, MD Faculty: Maurizio Gallieni, MD Drs. Steven Fishbane and Maurizio Gallieni discuss chronic kidney disease-associated pruritus (CKD-aP), a prevalent and under-recognized complication of CKD. They review the epidemiology, pathophysiology, and treatment strategies supported by pivotal phase 3 trials and new European S2k guidelines, including the use of difelikefalin, a kap...

Faculty: Prof. Dr. Johann Bauersachs Faculty: Carolyn S. P. Lam, MBBS, PhD Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitaliz...

Faculty: Prof. Dr. Johann Bauersachs Faculty: Carolyn S. P. Lam, MBBS, PhD Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitaliz...

Faculty: Prof. Dr. Johann Bauersachs Faculty: Javed Butler, MD Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, despi...

Faculty: Javed Butler, MD Faculty: Carolyn S. P. Lam, MBBS, PhD Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, desp...

Faculty: Javed Butler, MD Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, despite adherence to quadruple guideline-d...

Faculty: Prof. Dr. Johann Bauersachs Faculty: Carolyn S. P. Lam, MBBS, PhD Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitaliz...

Faculty: Prof. Dr. Johann Bauersachs Faculty: Carolyn S. P. Lam, MBBS, PhD Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitaliz...

Faculty: Prof. Dr. Johann Bauersachs Faculty: Javed Butler, MD Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, despi...

Faculty: Javed Butler, MD Faculty: Carolyn S. P. Lam, MBBS, PhD Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, desp...

Faculty: Javed Butler, MD Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, despite adherence to quadruple guideline-d...